145 related articles for article (PubMed ID: 24344400)
1. Combination of strong MMP-2 and weak TIMP-2 immunostainings is a significant prognostic factor in endometrial carcinoma.
Honkavuori-Toivola M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
Dis Markers; 2013; 35(4):261-6. PubMed ID: 24344400
[TBL] [Abstract][Full Text] [Related]
2. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.
Graesslin O; Cortez A; Uzan C; Birembaut P; Quereux C; Daraï E
Int J Gynecol Cancer; 2006; 16(5):1911-7. PubMed ID: 17009991
[TBL] [Abstract][Full Text] [Related]
3. Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.
Honkavuori-Toivola M; Talvensaari-Mattila A; Soini Y; Turpeenniemi-Hujanen T; Santala M
Tumour Biol; 2012 Aug; 33(4):935-41. PubMed ID: 22270451
[TBL] [Abstract][Full Text] [Related]
4. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
5. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract][Full Text] [Related]
6. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
[TBL] [Abstract][Full Text] [Related]
7. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels.
Davidson B; Reich R; Berner A; Givant-Horwitz V; Goldberg I; Risberg B; Kristensen GB; Trope CG; Bryne M; Kopolovic J; Nesland JM
Eur J Cancer; 2001 Nov; 37(16):2040-9. PubMed ID: 11597382
[TBL] [Abstract][Full Text] [Related]
8. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
9. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.
Graesslin O; Cortez A; Fauvet R; Lorenzato M; Birembaut P; Daraï E
Ann Oncol; 2006 Apr; 17(4):637-45. PubMed ID: 16407419
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
Alakus H; Grass G; Hennecken JK; Bollschweiler E; Schulte C; Drebber U; Baldus SE; Metzger R; Hölscher AH; Mönig SP
Histol Histopathol; 2008 Aug; 23(8):917-23. PubMed ID: 18498066
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
12. Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma.
Svagzdys S; Lesauskaite V; Pangonyte D; Saladzinskas Z; Tamelis A; Pavalkis D
Tohoku J Exp Med; 2011 Jan; 223(1):67-73. PubMed ID: 21212604
[TBL] [Abstract][Full Text] [Related]
13. Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
Obokata A; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Kuramoto H
Anticancer Res; 2007; 27(1A):95-105. PubMed ID: 17352221
[TBL] [Abstract][Full Text] [Related]
14. Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix.
Wang PH; Ko JL; Yang SF; Tsai HT; Tee YT; Han CP; Lin LY; Chen SC; Shih YT
Reprod Sci; 2011 Aug; 18(8):798-808. PubMed ID: 21422052
[TBL] [Abstract][Full Text] [Related]
15. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
16. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Nesland JM; Berner A; Bryne M; Reich R
Clin Exp Metastasis; 1999; 17(10):799-808. PubMed ID: 11089877
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
18. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.
Talvensaari-Mattila A; Santala M; Soini Y; Turpeenniemi-Hujanen T
Anticancer Res; 2005; 25(6B):4101-5. PubMed ID: 16309203
[TBL] [Abstract][Full Text] [Related]
20. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
